|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTC32 |
Gene summary for TTC32 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTC32 | Gene ID | 130502 |
| Gene name | tetratricopeptide repeat domain 32 | |
| Gene Alias | TTC32 | |
| Cytomap | 2p24.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q5I0X7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 130502 | TTC32 | LZE4T | Human | Esophagus | ESCC | 2.11e-08 | 2.65e-01 | 0.0811 |
| 130502 | TTC32 | LZE7T | Human | Esophagus | ESCC | 5.48e-13 | 6.17e-01 | 0.0667 |
| 130502 | TTC32 | LZE8T | Human | Esophagus | ESCC | 1.87e-03 | 9.01e-02 | 0.067 |
| 130502 | TTC32 | LZE22T | Human | Esophagus | ESCC | 1.85e-03 | 3.98e-01 | 0.068 |
| 130502 | TTC32 | LZE24T | Human | Esophagus | ESCC | 5.03e-13 | 2.68e-01 | 0.0596 |
| 130502 | TTC32 | LZE6T | Human | Esophagus | ESCC | 9.38e-04 | 2.68e-01 | 0.0845 |
| 130502 | TTC32 | P1T-E | Human | Esophagus | ESCC | 9.22e-07 | 1.98e-01 | 0.0875 |
| 130502 | TTC32 | P2T-E | Human | Esophagus | ESCC | 6.79e-33 | 5.14e-01 | 0.1177 |
| 130502 | TTC32 | P4T-E | Human | Esophagus | ESCC | 2.62e-08 | 2.43e-01 | 0.1323 |
| 130502 | TTC32 | P5T-E | Human | Esophagus | ESCC | 2.71e-07 | 1.03e-01 | 0.1327 |
| 130502 | TTC32 | P8T-E | Human | Esophagus | ESCC | 2.04e-20 | 4.51e-01 | 0.0889 |
| 130502 | TTC32 | P9T-E | Human | Esophagus | ESCC | 4.60e-12 | 1.91e-01 | 0.1131 |
| 130502 | TTC32 | P10T-E | Human | Esophagus | ESCC | 2.54e-24 | 4.16e-01 | 0.116 |
| 130502 | TTC32 | P11T-E | Human | Esophagus | ESCC | 1.60e-02 | 2.37e-01 | 0.1426 |
| 130502 | TTC32 | P12T-E | Human | Esophagus | ESCC | 2.16e-17 | 2.98e-01 | 0.1122 |
| 130502 | TTC32 | P15T-E | Human | Esophagus | ESCC | 1.60e-04 | 1.09e-01 | 0.1149 |
| 130502 | TTC32 | P16T-E | Human | Esophagus | ESCC | 4.86e-07 | 1.22e-01 | 0.1153 |
| 130502 | TTC32 | P17T-E | Human | Esophagus | ESCC | 5.52e-04 | 1.64e-01 | 0.1278 |
| 130502 | TTC32 | P19T-E | Human | Esophagus | ESCC | 6.12e-03 | 3.02e-01 | 0.1662 |
| 130502 | TTC32 | P20T-E | Human | Esophagus | ESCC | 8.02e-18 | 3.63e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTC32 | insertion | Frame_Shift_Ins | novel | c.9_10insTTCGCCGGTGCGCTTGCGCGGCCTC | p.Gln4PhefsTer60 | p.Q4Ffs*60 | Q5I0X7 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| TTC32 | insertion | Frame_Shift_Ins | novel | c.8_9insCACTGTACTCCGCTTAC | p.Gln4ThrfsTer15 | p.Q4Tfs*15 | Q5I0X7 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| TTC32 | SNV | Missense_Mutation | rs748980235 | c.50N>T | p.Ala17Val | p.A17V | Q5I0X7 | protein_coding | tolerated(0.06) | possibly_damaging(0.741) | TCGA-AA-3955-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | capecitabine | CR |
| TTC32 | SNV | Missense_Mutation | c.323N>G | p.Phe108Cys | p.F108C | Q5I0X7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-5254-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| TTC32 | SNV | Missense_Mutation | novel | c.143C>A | p.Pro48His | p.P48H | Q5I0X7 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TTC32 | SNV | Missense_Mutation | c.431N>T | p.Arg144Ile | p.R144I | Q5I0X7 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TTC32 | SNV | Missense_Mutation | c.68A>C | p.Glu23Ala | p.E23A | Q5I0X7 | protein_coding | tolerated(0.25) | benign(0.007) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TTC32 | SNV | Missense_Mutation | rs751251296 | c.307N>C | p.Tyr103His | p.Y103H | Q5I0X7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC32 | insertion | Frame_Shift_Ins | novel | c.426dupA | p.Gln143ThrfsTer15 | p.Q143Tfs*15 | Q5I0X7 | protein_coding | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| TTC32 | SNV | Missense_Mutation | rs149286415 | c.326A>T | p.Asp109Val | p.D109V | Q5I0X7 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-50-5051-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |